1. Camacho LH, Frost CP, Abella E, Morrow PK, Whittaker S. Biosimilars 101: considerations for U.S. oncologists in clinical practice. Cancer Med. 2014;3(4):889–99. doi: 10.1002/cam4.258 .
2. FDA. FDA 101: regulating biological products. 25 July 2008. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048341.htm . Accessed 15 Sept 2016.
3. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72(3):315–8. doi: 10.1136/annrheumdis-2012-202941 .
4. FDA. Frequently asked questions on patents and exclusivity. What is the difference between patents and exclusivity? 2014. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079031.htm . Accessed 15 Sept 2016.
5. Generic Pharmaceutical Association. Generic drug savings in the U.S. Seventh annual edition: 2015. http://www.gphaonline.org/media/wysiwyg/PDF/GPhA_Savings_Report_2015.pdf . Accessed 16 Dec 2016.